TABLE 1.
Patient Characteristics and Symptom Severity*
| n | % | Baseline† mean (SD) | Symptom peak (day +11) mean (SD) | ||
|---|---|---|---|---|---|
| Age | Younger than 50 | 13 | 43.3 | 2.04 (2.36) | 4.08 (2.29) |
| 50 to 59 | 9 | 30.0 | 1.78 (1.60) | 5.24 (2.18) | |
| 60 and older | 8 | 26.7 | 1.35 (0.90) | 4.78 (2.21) | |
| Sex | Male | 17 | 56.7 | 1.81 (1.64) | 4.22 (2.13) |
| Female | 13 | 43.3 | 1.73 (2.09) | 5.13 (2.32) | |
| Race | White | 22 | 73.3 | 2.19 (1.94) ‡ | 5.09 (1.96) |
| Asian, Black, and Hispanic | 8 | 26.7 | 0.65 (0.61) ‡ | 3.31 (1.96) | |
| Education | College or higher | 27 | 90.0 | 1.88 (1.88) | 4.68 (2.17) |
| High school | 3 | 10.0 | 0.89 (0.67) | 4.06 (3.08) | |
| Pretransplantation disease status | Complete remission | 18 | 60.0 | 1.73 (1.79) | 4.71 (2.08) |
| Relapse | 9 | 30.0 | 1.67 (1.71) | 4.15 (2.64) | |
| Other | 3 | 10.0 | 2.39 (2.84) | 5.44 (2.14) | |
| Reduced-intensity conditioning regimen | No | 17 | 56.7 | 1.82 (1.88) | 4.76 (2.34) |
| Yes | 13 | 43.3 | 1.75 (1.82) | 4.51 (2.19) | |
| Degree of matching | Sibling | 13 | 43.3 | 1.92 (2.26) | 4.42 (2.75) |
| Unrelated donor | 17 | 56.7 | 1.67 (1.45) | 4.76 (1.79) | |
| Source of cell product | Bone marrow | 13 | 43.3 | 1.23 (0.97) | 4.37 (1.63) |
| Peripheral blood stem cells | 17 | 56.7 | 2.20 (2.20) | 4.80 (2.62) | |
| Type of disease | AML | 14 | 46.7 | 1.63 (2.05) | 4.60 (2.48) |
| MDS | 5 | 16.7 | 2.80 (2.70) | 4.83 (1.76) | |
| MDS to AML | 11 | 36.6 | 1.50 (0.73) | 4.54 (2.25) |
SD indicates standard deviation; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome.
*
6 symptoms (pain, fatigue, sleep disturbance, dry mouth, lack of appetite, and drowsiness) had the highest mean severity at symptom peak (day +11 after allo-HSCT).
†
Baseline data were collected on the day of hospital admission, an average of 5.5 days before conditioning.
‡
P < .01 by Wilcoxon rank sum test comparing the component symptom score at baseline between groups.